File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Risk factors and outcomes of extended-spectrum beta-lactamase-producing E. coli peritonitis in CAPD patients

TitleRisk factors and outcomes of extended-spectrum beta-lactamase-producing E. coli peritonitis in CAPD patients
Authors
KeywordsCephalosporin
E coli
Extended-spectrum beta-lactamase
Gastric acid inhibitor
Peritonitis
Issue Date2006
PublisherMultimed, Inc. The Journal's web site is located at http://pdiconnect.com
Citation
Peritoneal Dialysis International, 2006, v. 26 n. 2, p. 191-197 How to Cite?
Abstract
◆ Objective: To determine the risk factors and outcomes of peritonitis caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli in continuous ambulatory peritoneal dialysis (CAPD). ◆ Patients and Methods: Episodes of E. coli CAPD peritonitis in our unit from October 1994 to August 2003 were reviewed. Demographic data, underlying medical conditions, recent use of gastric add inhibitors (including H2 antagonist and proton pump inhibitor), recent antibiotic therapy, antibiotic regimen for peritonitis episodes, sensitivity test results of the E. coli isolated, and clinical outcomes were examined. ◆ Results: Over a 10-year study period, 88 episodes of E. coli peritonitis were recorded; 11 of the 88 cases were caused by ESBL-producing E. coli. Recent use of cephalosporins and gastric acid inhibitor were associated with the development of ESBL-producing E. coli peritonitis. Compared with non-ESBL-produdng E. coli peritonitis, more cases in the ESBL-producing E. coli group developed treatment failure (45.5% vs 13.0%, p = 0.02) and died of sepsis (27.3% vs 3.9%, p = 0.02). Peritoneal failure rate was higher in the ESBL-producing E. coli group, although the difference was not statistically significant (18.2% vs 3.9%, p = 0.12). ◆ Conclusion: Peritonitis caused by ESBL-producing E. coli is associated with worse clinical outcomes. The use of cephalosporins and gastric acid inhibitors may contribute to its development. Further studies are warranted to investigate and determine the predisposing factors for ESBL-producing E. coli peritonitis. Copyright © 2006 International Society for Peritoneal Dialysis.
Persistent Identifierhttp://hdl.handle.net/10722/162957
ISSN
2013 Impact Factor: 2.199
2013 SCImago Journal Rankings: 1.189
ISI Accession Number ID
References

 

Author Affiliations
  1. The University of Hong Kong
DC FieldValueLanguage
dc.contributor.authorYip, Ten_HK
dc.contributor.authorTse, KCen_HK
dc.contributor.authorLam, MFen_HK
dc.contributor.authorTang, Sen_HK
dc.contributor.authorLi, FKen_HK
dc.contributor.authorChoy, BYen_HK
dc.contributor.authorLui, SLen_HK
dc.contributor.authorChan, TMen_HK
dc.contributor.authorLai, KNen_HK
dc.contributor.authorLo, WKen_HK
dc.date.accessioned2012-09-05T05:25:53Z-
dc.date.available2012-09-05T05:25:53Z-
dc.date.issued2006en_HK
dc.identifier.citationPeritoneal Dialysis International, 2006, v. 26 n. 2, p. 191-197en_HK
dc.identifier.issn0896-8608en_HK
dc.identifier.urihttp://hdl.handle.net/10722/162957-
dc.description.abstract◆ Objective: To determine the risk factors and outcomes of peritonitis caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli in continuous ambulatory peritoneal dialysis (CAPD). ◆ Patients and Methods: Episodes of E. coli CAPD peritonitis in our unit from October 1994 to August 2003 were reviewed. Demographic data, underlying medical conditions, recent use of gastric add inhibitors (including H2 antagonist and proton pump inhibitor), recent antibiotic therapy, antibiotic regimen for peritonitis episodes, sensitivity test results of the E. coli isolated, and clinical outcomes were examined. ◆ Results: Over a 10-year study period, 88 episodes of E. coli peritonitis were recorded; 11 of the 88 cases were caused by ESBL-producing E. coli. Recent use of cephalosporins and gastric acid inhibitor were associated with the development of ESBL-producing E. coli peritonitis. Compared with non-ESBL-produdng E. coli peritonitis, more cases in the ESBL-producing E. coli group developed treatment failure (45.5% vs 13.0%, p = 0.02) and died of sepsis (27.3% vs 3.9%, p = 0.02). Peritoneal failure rate was higher in the ESBL-producing E. coli group, although the difference was not statistically significant (18.2% vs 3.9%, p = 0.12). ◆ Conclusion: Peritonitis caused by ESBL-producing E. coli is associated with worse clinical outcomes. The use of cephalosporins and gastric acid inhibitors may contribute to its development. Further studies are warranted to investigate and determine the predisposing factors for ESBL-producing E. coli peritonitis. Copyright © 2006 International Society for Peritoneal Dialysis.en_HK
dc.languageengen_US
dc.publisherMultimed, Inc. The Journal's web site is located at http://pdiconnect.comen_HK
dc.relation.ispartofPeritoneal Dialysis Internationalen_HK
dc.subjectCephalosporinen_HK
dc.subjectE colien_HK
dc.subjectExtended-spectrum beta-lactamaseen_HK
dc.subjectGastric acid inhibitoren_HK
dc.subjectPeritonitisen_HK
dc.subject.meshAgeden_US
dc.subject.meshEscherichia Coli - Enzymologyen_US
dc.subject.meshEscherichia Coli Infectionsen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPeritoneal Dialysis, Continuous Ambulatoryen_US
dc.subject.meshPeritonitis - Microbiologyen_US
dc.subject.meshRisk Factorsen_US
dc.subject.meshBeta-Lactamases - Biosynthesisen_US
dc.titleRisk factors and outcomes of extended-spectrum beta-lactamase-producing E. coli peritonitis in CAPD patientsen_HK
dc.typeArticleen_HK
dc.identifier.emailTang, S: scwtang@hku.hken_HK
dc.identifier.emailChan, TM: dtmchan@hku.hken_HK
dc.identifier.emailLai, KN: knlai@hku.hken_HK
dc.identifier.authorityTang, S=rp00480en_HK
dc.identifier.authorityChan, TM=rp00394en_HK
dc.identifier.authorityLai, KN=rp00324en_HK
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.pmid16623424en_HK
dc.identifier.scopuseid_2-s2.0-33645510764en_HK
dc.identifier.hkuros117896-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33645510764&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume26en_HK
dc.identifier.issue2en_HK
dc.identifier.spage191en_HK
dc.identifier.epage197en_HK
dc.identifier.isiWOS:000237003600013-
dc.publisher.placeCanadaen_HK
dc.identifier.scopusauthoridYip, T=7004283977en_HK
dc.identifier.scopusauthoridTse, KC=7102609864en_HK
dc.identifier.scopusauthoridLam, MF=7202630163en_HK
dc.identifier.scopusauthoridTang, S=7403437082en_HK
dc.identifier.scopusauthoridLi, FK=8219093900en_HK
dc.identifier.scopusauthoridChoy, BY=7003465499en_HK
dc.identifier.scopusauthoridLui, SL=7102379130en_HK
dc.identifier.scopusauthoridChan, TM=7402687700en_HK
dc.identifier.scopusauthoridLai, KN=7402135706en_HK
dc.identifier.scopusauthoridLo, WK=7201502414en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats